Chris Weyrer, MD, PhD

Principal at Vida Ventures; acting Chief Business Officer

Appears in 1 story

Last updated Oct 25, 2026

Stories

FDA clears Protego's pivotal trial of PROT-001 for AL amyloidosis

New Capabilities

Board seat at Protego

The Food and Drug Administration cleared Protego Biopharma to start SHIELD-AL, a Phase 2/3 trial of PROT-001 in newly diagnosed lambda light chain AL amyloidosis. Protego says the study is planned to begin in the first quarter of 2027.

Updated Oct 25